PPARD and hepatocellular carcinoma: A prospective one-arm, multicenter phase II clinical trial evaluated the progression-free survival, safety and tolerability of a metronomic chemotherapy, which included capecitabine, rofecoxib (PPARγ agonist, and PPARβ antagonist) and pioglitazone, a PPARγ agonist in 38 patients with non-curative HCC, and the median progression-free survival was 2.7 months, the median overall survival was 6.7 months [114].